Jeffrey Wagner

List of Publications by Year
in descending order

45 papers	3,296 citations	185998 28 h-index	233125 45 g-index
45 all docs	45 docs citations	45 times ranked	2636 citing authors

#	Article	IF	Citations
1	Early Pulmonary Inflammation in Infants with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 1995, 151, 1075-1082.	2.5	545
2	Risk Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and Adolescents with Cystic Fibrosis. Journal of Pediatrics, 2007, 151, 134-139.e1.	0.9	384
3	Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. Journal of Pediatrics, 2003, 142, 624-630.	0.9	355
4	Impact of Pregnancy on Women With Cystic Fibrosis. Chest, 2006, 129, 706-711.	0.4	165
5	Presence of methicillin resistantStaphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatric Pulmonology, 2007, 42, 513-518.	1.0	139
6	Impact of Socioeconomic Status, Race, and Ethnicity on Quality of Life in Patients With Cystic Fibrosis in the United States. Chest, 2010, 137, 642-650.	0.4	110
7	Lung function decline from adolescence to young adulthood in cystic fibrosis. Pediatric Pulmonology, 2012, 47, 135-143.	1.0	99
8	Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatric Pulmonology, 2013, 48, 666-673.	1.0	99
9	Year-to-year changes in lung function in individuals with cystic fibrosis. Journal of Cystic Fibrosis, 2010, 9, 250-256.	0.3	98
10	Risk factors for rate of decline in FEV1 in adults with cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 405-411.	0.3	96
11	Association of Socioeconomic Status with the Use of Chronic Therapies and Healthcare Utilization in Children with Cystic Fibrosis. Journal of Pediatrics, 2009, 155, 634-639.e4.	0.9	92
12	Longitudinal assessment of healthâ€•related quality of life in an observational cohort of patients with cystic fibrosis. Pediatric Pulmonology, 2011, 46, 36-44.	1.0	85
13	The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Pediatric Pulmonology, 2008, 43, 1117-1123.	1.0	77
14	Clinical use of dornase alfa is associated with a slower rate of FEV₁ decline in cystic fibrosis. Pediatric Pulmonology, 2011, 46, 545-553.	1.0	76
15	Relationship between Inhaled Corticosteroid Therapy and Rate of Lung Function Decline in Children with Cystic Fibrosis. Journal of Pediatrics, 2008, 153, 746-751.e2.	0.9	72
16	Newborn screening for cystic fibrosis. Current Opinion in Pediatrics, 2012, 24, 329-335.	1.0	69
17	Infant Care Patterns at Epidemiologic Study of Cystic Fibrosis Sites That Achieve Superior Childhood Lung Function. Pediatrics, 2007, 119, e531-e537.	1.0	60
18	Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatric Pulmonology, 2010, 45, 1167-1172.	1.0	58

#	Article	IF	Citations
19	Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatric Pulmonology, 2008, 43, 874-881.	1.0	56
20	Pulmonary exacerbations in cystic fibrosis: Young children with characteristic signs and symptoms. Pediatric Pulmonology, 2013, 48, 649-657.	1.0	44
21	Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. Journal of Pediatrics, 2016, 169, 116-121.e2.	0.9	44
22	Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. Pediatric Pulmonology, 2010, 45, 1156-1166.	1.0	39
23	Socioeconomic Status and the Likelihood of Antibiotic Treatment for Signs and Symptoms of Pulmonary Exacerbation in Children with Cystic Fibrosis. Journal of Pediatrics, 2011, 159, 819-824.e1.	0.9	36
24	Probability of Treatment Following Acute Decline in Lung Function in Children with Cystic Fibrosis is Related to Baseline Pulmonary Function. Journal of Pediatrics, 2013, 163, 1152-1157.e2.	0.9	36
25	Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis, 2018, 17, 83-88.	0.3	36
26	Relationship of Antibiotic Treatment to Recovery after Acute FEV₁ Decline in Children with Cystic Fibrosis. Annals of the American Thoracic Society, 2017, 14, 937-942.	1.5	35
27	Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United States. Current Medical Research and Opinion, 2017, 33, 667-674.	0.9	32
28	Cystic fibrosis: current trends in respiratory care. Respiratory Care, 2003, 48, 234-45; discussion 246-7.	0.8	31
29	Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study. BMJ: British Medical Journal, 2018, 360, k668.	2.4	28
30	Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. Pediatric Pulmonology, 2008, 43, 739-744.	1.0	21
31	Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis. Pediatric Pulmonology, 2020, 55, 828-834.	1.0	21
32	BMI fails to identify poor nutritional status in stunted children with CF. Journal of Cystic Fibrosis, 2017, 16, 158-160.	0.3	20
33	Clinical use of tobramycin inhalation solution (TOBIÂ®) shows sustained improvement in FEV₁ in cystic fibrosis. Pediatric Pulmonology, 2014, 49, 529-536.	1.0	16
34	Pulmonary function outcomes for assessing cystic fibrosis care. Journal of Cystic Fibrosis, 2015, 14, 376-383.	0.3	16
35	Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 496-502.	0.3	15
36	A debate on why my state (province) should or should not conduct newborn screening for cystic fibrosis (14th Annual North American Cystic Fibrosis Conference). Pediatric Pulmonology, 2001, 32, 385-396.	1.0	14

#	Article	IF	Citations
37	Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis. Journal of Medical Economics, 2016, 19, 845-851.	1.0	13
38	Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study. Journal of the American Heart Association, 2021, 10, e020377.	1.6	12
39	Epidemiologic Study of Cystic Fibrosis: 25 years of observational research. Pediatric Pulmonology, 2021, 56, 823-836.	1.0	11
40	Update on newborn screening for cystic fibrosis. Current Opinion in Pulmonary Medicine, 2004, 10, 500-504.	1.2	10
41	Strengthening care teams to improve adherence in cystic fibrosis: a qualitative practice assessment and quality improvement initiative. Patient Preference and Adherence, 2017, Volume 11, 761-767.	0.8	9
42	Liver Involvement in the Hispanic Population of North America With Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition, 2014, 59, 476-479.	0.9	7
43	Improving performance in the detection and management of cystic fibrosis-related diabetes in the Mountain West Cystic Fibrosis Consortium. BMJ Open Diabetes Research and Care, 2016, 4, e000183.	1.2	7
44	Comparison of FEV1 reference equations for evaluating a cystic fibrosis therapeutic intervention. Pediatric Pulmonology, 2017, 52, 1013-1019.	1.0	6
45	VT or Not VT?. Circulation, 2020, 142, 605-607.	1.6	2